Company overview
PacBio provides highly accurate long-read sequencing technology (HiFi reads with 99.9% accuracy) for genome, transcriptome, and epigenome analysis. The platform enables de novo genome assemblies, structural variant detection, and full-length transcript sequencing without assembly. PacBio serves pharmaceutical R&D applications including plasmid sequencing, cell line verification, mRNA polyA tail measurement, and directed evolution studies.
Pacific is listed in the NovaPharmaNews Supplier Hub as a Diagnostics & Testing partner serving United States & Americas. Core focus areas include long-read sequencing, hifi sequencing, genome assembly, pharmaceutical r&d, epigenetic detection.
Industry categories: Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://www.pacb.com
- Categories
- Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- long-read sequencing, hifi sequencing, genome assembly, pharmaceutical r&d, epigenetic detection
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What sequencing accuracy does PacBio HiFi technology achieve?
- PacBio HiFi reads deliver 99.9% accuracy, matching the performance of short-read sequencing and Sanger sequencing while providing significantly longer read lengths.
- What are the primary applications for pharmaceutical R&D?
- Key applications include plasmid sequencing, cell line sequencing and verification, mRNA polyA tail measurement, directed evolution studies, and full-length transcript sequencing for biologics development.
- How does PacBio compare to second-generation sequencing technologies?
- PacBio offers much longer read lengths and faster runs than second-generation sequencing, enabling de novo genome assemblies and structural variant detection. However, it has lower throughput and higher cost, making it complementary to short-read technologies for comprehensive genomic analysis.
- Can PacBio detect epigenetic modifications?
- Yes, PacBio sequencing detects native base modifications including m6A and m4C epigenetic motifs during sequencing, even in low-coverage and high-contamination scenarios, without requiring separate assays.
- What is the advantage of long-read sequencing for genome assembly?
- Long reads enable highly contiguous de novo assemblies that close gaps in reference genomes, characterize structural variations in personal genomes, and provide reliable scaffolds for complex genomic regions.
Related editorial coverage
- Pharma R&D ROI: A Multidimensional Framework for AI Investment Success
- Eli Lilly Dominates Pharma R&D Performance Rankings, Setting New Benchmarks
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
Explore lab tools and QA/QC resources for R&D teams.
